Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer | Docwire News Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.

Dr Sara Nunnery breaks down the evolving HER2 classification system and the clinical impact of DESTINY-Breast06. Hear how #Enhertu is reshaping treatment for HR+/HER2-low #BreastCancer. Watch now ⬇️ docwirenews.com/post/reclass... #HER2Low #DESTINYBreast06 #Oncology #CancerResearch